Keytruda (pembrolizumab)

Numéro de dossier de l’APP: 22014
État des négociations:
Négociation conclue par une lettre d’intention
Indication(s):
in combination with Lenvatinib (Lenvima) for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.
Promoteur/fabricant:
Merck Canada
Numéro de projet de l’ACMTS:
PC0288
Lettre-contrat de l’APP:
Conclusion du processus de négociation: